A hand-held device which could offer point-of-care blood cell analysis in doctors’ surgeries is being developed by academics at the University of Southampton and is described in a paper in Lab on a Chip this month.
Search Results for: point-of-care
John McDonough, CEO of Cambridge, Mass.-based T2 Biosystems Inc., is an optimist.
Bullish on his 22-employee company’s prospects (the estimated $40 billion diagnostics market might have something to do with that), McDonough (far left in the picture at right) spoke with MassDevice about the technology behind T2’s diagnostic device, which uses a miniaturized version of a magnetic resonance imaging machine to deliver near-instant test results from just about any blood, urine or saliva sample.
Brain micro-electrodes create new possibilities: Neurosurgeons from the University of Utah have developed new tiny electrode arrays that do not penetrate the surface of the brain, potentially preventing many of the side effects common to modern high precision electrodes. Similar to electrocorticography arrays, the micro-ECoG devices may be small enough for permanent placement under the skull.
Osmetech Inc. raised $8.6 million in a stock offering by selling a roughly 30 percent stake to investors.
The London-based molecular diagnostics maker, which has operations in Maynard, said it will name a new board chairmen with deep ties in the diagnostics field.
Christopher Gleeson, the former CEO of Ventana Medical Systems Inc. of Tuscon, Ariz., and a former board member at Roche Diagnostics, will become chairman of the company’s board July 1. Gleeson invested $1 million in Osmetech during the stock sale.
LaViolette rose from senior vice president and group president of several divisions to become the Natick device giant’s chief operating officer in 2004.
Pleasanton, Calif.-based Thoratec, which has operations in Burlington, develops devices to treat advanced-stage heart failure, point-of-care blood testing and skin incision products.
Osmetech Inc. asked the Food & Drug Administration for emergency approval to use its Respiratory Pathogen Test Panel to screen for the Swine Flu.
The London-based molecular diagnostics maker, which has operations in Maynard, is the latest company to enter the H1N1 virus diagnostics race.
Inverness Medical Innovations Inc. first told the Centers for Disease Control that it stood ready to supply point-of-care tests for the virus.
Twelve of the 32 companies given Excellence in Medical Technologies & Life Sciences awards by Frost & Sullivan have roots in the Bay State.
The global research firm’s annual awards recognize companies that have made major contributions to the medical device, pharmaceutical, biotech and drug discovery and other healthcare fields.
The in-vitro diagnostic market, now dominated by the United States, Europe and Japan, will undergo a sea change as emerging countries take market share from the Big Three, according to a Frost & Sullivan report.
The three largest players, which owned 90 percent of the market at the end of 2007, will increasingly lose market share to such nations as India, Brazil and China in the next few years, the consulting company predicted.
MedAptus tapped its lead investor for another round of financing aimed at growing its suite of handheld products that help physicians more efficiently code procedures for reimbursement.
In a post-event haze fueled by rice and curry chicken (the 2009 Annual Life Sciences Venture Capital Outlook Event was held by The Indus Entrepreneurs), I can conclude that medtech in Massachusetts continues to be a great place to innovate and invest, but as entrepreneurs we need to pause to let the markets settle down a bit before raising more funding.
About 100 venture capitalists, entrepreneurs, and students sat down March 11 in a Harvard Business School lecture room for two presentations by local MedTech entrepreneurs.